TABLE 2.
Association between SOD1 expression and clinicopathological characteristics patients with NSCLC.
| SOD1 expression |
||||
| Variable | All patients | High (%) | Low (%) | P |
| (n = 196) | (n = 122) | (n = 74) | ||
| Smoking | ||||
| Never | 80 | 53 (43) | 27 (36) | 0.337 |
| Ever | 116 | 69 (57) | 47 (64) | |
| Gender | ||||
| Male | 129 | 79 (65) | 50 (68) | 0.687 |
| Female | 67 | 43 (35) | 24 (32) | |
| Age (years) | ||||
| <60 | 89 | 54 (44) | 35 (47) | 0.679 |
| ≥60 | 107 | 68 (56) | 39 (53) | |
| Differentiation | ||||
| Well | 20 | 11(9) | 9 (12) | 0.846 |
| Moderate | 75 | 46 (37) | 29 (39) | |
| Poor | 101 | 65 (44) | 36 (49) | |
| Histological cell type | ||||
| Adenocarcinoma | 74 | 43 (35) | 31 (42) | 0.352 |
| Squamous cell carcinoma | 122 | 79 (65) | 43 (58) | |
| PStage | ||||
| I | 93 | 45 (37) | 48 (65) | < 0.001∗ |
| II | 40 | 25 (20) | 15 (20) | |
| III | 63 | 52 (43) | 11 (15) | |
| pT classification | ||||
| T1 | 34 | 14 (11) | 20 (27) | 0.011∗ |
| T2 | 129 | 82 (67) | 47 (64) | |
| T3/4 | 33 | 27 (22) | 7 (9) | |
| Lymph node metastasis | < 0.001∗ | |||
| N0 | 114 | 56 (46) | 58 (78) | |
| N1 | 26 | 17 (14) | 9 (12) | |
| N2 | 56 | 49 (40) | 7 (10) | |
| Adjuvant chemotherapy | ||||
| Yes | 121 | 76 (62) | 45 (61) | 0.836 |
| No | 75 | 46 (38) | 29 (39) | |
| Adjuvant radiotherapy | ||||
| Yes | 89 | 59 (48) | 30 (41) | 0.286 |
| No | 107 | 63 (52) | 44 (59) | |
Abbreviations: NSCLC, non-small cell lung cancer; pTNM stage, tumor node metastasis (pathological stage); pT, pathological T stage; n, number of patients. Ever, smoking at any time from the beginning of life. P-value, the difference of clinicopathological characteristics between the SOD1 high expression group and low expression group. ∗P < 0.05 was considered statistically significant.